The Week Ahead: Fed...
Health Care: Drugs
Dyax Corporation (DYAX: NASDAQ)
$1.87 0.07 | 3.89%
06/04/12 - 09:59 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.80 |
| 52 Week High | 2.17 |
| 52 Week Low | 1.10 |
| Avg. Daily Vol. (Mil) | 0.24 |
| Beta (3 year) | 1.66 |
| Share Related Items | |
| Mkt Cap (Mil) | 177.84 |
| Shares Out (Mil) | 98.80 |
| Float (Mil) | 77.73 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.50 |
| Current Ratio | 3.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.42 |
| Price/Book | 0.00 |
| Price/Cash Flow | -5.40 |
| Per Share Data | |
| Earnings | -0.35 |
| Sales | 0.53 |
| Book Value | 0.00 |
| Cash Flow | -0.33 |
| Business Summary | |
|---|---|
| Dyax Corporation is a biotechnology company, which is engaged in the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. | |
| General Information | |
| 300 Technology Square
Cambridge, MA 02139 |
|
| www.dyax.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 120 | |
| CEO: Gustav A. Christensen | |
| Short Interest | |
| Current Month (Mil) | 4.24 |
| Previous Month (Mil) | 4.25 |
| Short Interest Ratio (Days) | 22.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -50.90 |
| Return on Investments | -92.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -46.90 |
| Profit Margin | -66.60 |
Portfolios with DYAX
- Portfolio NameUser Type
- UserSUPRATRADE-0303071618
- Userdulcinea
- ContributorOptions Action Portfolio Fe...
- UserLast Day of the JPMorgan He...
- UserBarron's Research Reports 7...
- UserPART 6 JPMorgan 26th Annual...
- Userpnp.v
- UserSpec #1
- Userjan's specs
- Userslarsen Portfolio 1
Latest DYAX Headlines from TheStreet
- Dyax's CEO Presents At Deutsche Bank AG Health Care Conference (Transcript) 05.07.12 | 03:05 pm
- Dyax Stock Gaps Down On Today's Open (DYAX) 07.19.11 | 09:07 am
- Dyax Corporation CEO Discusses Q3 2010 Results - Earnings Call Transcript 10.28.10 | 03:10 am
- Dyax Corp. Q2 2010 Earnings Call Transcript 07.28.10 | 10:07 pm
- Merck Buys British Maker Of Biotech Medicines 12.17.09 | 12:12 pm
- Cubist Stops Enrollment In Anti-bleeding Studies 12.03.09 | 01:12 pm
- Delta, Walgreen, Diedrich Coffee Are Big Movers 12.02.09 | 04:12 pm
- Dyax Shares Rocket On FDA Clearance For Kalbitor 12.02.09 | 11:12 am
- Dyax, RF Micro: Early Volume Plays 12.02.09 | 08:12 am
- FDA Approves Two New Drugs: BioBuzz 12.02.09 | 07:12 am
Press Releases for DYAX
- Dyax Announces Extension Of Partnership With Bayer For Access To Dyax’s Fully-Human Antibody Phage Display Library - Business Wire 05.30.12 | 08:05 am
- Dyax Corp. To Participate In The Jefferies 2012 Global Healthcare Conference - Business Wire 05.29.12 | 07:05 am
- Dyax Launches HAE Diagnostic Testing Refund Program To Encourage Proper Diagnosis And Disease Management - Business Wire 05.24.12 | 10:05 am
- "Dyax Employees Gather At Their Burlington, MA Corporate Headquarters To Take Part In The "Cover The World With Smiles" Campaign. The Initiative Asks Those From Around The World To Take A Picture Of Their 'smile', The Primary Symbol Of Hereditary Angioedema Awareness Day, To Demonstrate That People Everywhere Are Banding Together To Raise Awareness Of The Condition." (Photo: Business Wire) - Business Wire 05.16.12 | 08:05 am
- Dyax Corp. Launches Hereditary Angioedema (HAE) Attack Tracker™, A Free IPhone Application For HAE Patients - Business Wire 05.11.12 | 07:05 am
- Dyax Corp. To Participate In The Deutsche Bank 37th Annual Healthcare Conference - Business Wire 05.01.12 | 07:05 am
- Dyax Corp. To Host First Quarter 2012 Earnings Call And Webcast - Business Wire 04.18.12 | 07:04 am
- Dyax And Eclipse Therapeutics Announce Oncology Antibody License Agreement - Business Wire 04.17.12 | 07:04 am
- Dyax Launches Hereditary Angioedema Genetic Counseling Program To Educate Patients And Family Members About Disease And Inheritance - Business Wire 04.11.12 | 07:04 am
- GE Healthcare And Dyax Announce Licensing Agreement For C-Met Imaging Peptides For Use In Colorectal, Lung And Liver Cancer Research - Business Wire 03.31.12 | 08:03 am
Partner Headlines for DYAX
- Morning Market Losers - Benzinga 07.19.11 | 09:07 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.13.11 | 09:07 am
- Low-Priced Biotech Stocks With Insider Buying - Seeking Alpha 03.18.11 | 06:03 pm
- Dyax Corp. Hits New 52-Week Low (DYAX) - Benzinga 01.04.11 | 09:01 am
- UPDATE 1-Dyax, Sigma-Tau agree to develop, market genetic drug - Reuters 06.21.10 | 08:06 am
- CORRECTED - CORRECTED-UPDATE 1-Dyax posts narrower-than-expected Q4 loss - Reuters 02.17.10 | 09:02 am
